CN106937957A - A kind of application method for being used to treat the formula, shampoo and the formula of androgenetic alopecia - Google Patents
A kind of application method for being used to treat the formula, shampoo and the formula of androgenetic alopecia Download PDFInfo
- Publication number
- CN106937957A CN106937957A CN201710263979.5A CN201710263979A CN106937957A CN 106937957 A CN106937957 A CN 106937957A CN 201710263979 A CN201710263979 A CN 201710263979A CN 106937957 A CN106937957 A CN 106937957A
- Authority
- CN
- China
- Prior art keywords
- formula
- vitamin
- hair
- androgenetic alopecia
- treat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 53
- 239000002453 shampoo Substances 0.000 title claims abstract description 23
- 206010068168 androgenetic alopecia Diseases 0.000 title claims abstract description 22
- 201000002996 androgenic alopecia Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 14
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 22
- 238000003756 stirring Methods 0.000 claims abstract description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 16
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 16
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 16
- 229940025878 hesperidin Drugs 0.000 claims abstract description 16
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 16
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 16
- 239000011720 vitamin B Substances 0.000 claims abstract description 16
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 15
- -1 nonanedioyl Chemical group 0.000 claims abstract description 15
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011591 potassium Substances 0.000 claims abstract description 14
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 239000008367 deionised water Substances 0.000 claims abstract description 6
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 241000241413 Propolis Species 0.000 claims description 9
- 229940069949 propolis Drugs 0.000 claims description 9
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- 229930003571 Vitamin B5 Natural products 0.000 claims description 5
- 229960002079 calcium pantothenate Drugs 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 235000009492 vitamin B5 Nutrition 0.000 claims description 5
- 239000011675 vitamin B5 Substances 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 4
- 235000021468 vitamin B8 Nutrition 0.000 claims description 4
- 125000003201 pantothenic acid group Chemical group 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 claims 1
- 240000003243 Thuja occidentalis Species 0.000 claims 1
- 235000008109 Thuja occidentalis Nutrition 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 210000004209 hair Anatomy 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 29
- 108090000854 Oxidoreductases Proteins 0.000 abstract description 21
- 102000004316 Oxidoreductases Human genes 0.000 abstract description 21
- 210000003780 hair follicle Anatomy 0.000 abstract description 18
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract description 17
- 108091007187 Reductases Proteins 0.000 abstract description 16
- 230000012010 growth Effects 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 14
- 210000004761 scalp Anatomy 0.000 abstract description 13
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 abstract description 10
- 229960003632 minoxidil Drugs 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- 238000013019 agitation Methods 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 231100000360 alopecia Toxicity 0.000 description 19
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 14
- 238000007790 scraping Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003098 androgen Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 238000010422 painting Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000003778 catagen phase Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000218691 Cupressaceae Species 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 1
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010066295 Keratosis pilaris Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of application method for being used to treat the formula, shampoo and the formula of androgenetic alopecia, the formula includes nonanedioyl Diglycocol potassium 41% 50%, Water-soluble Hesperidin 6% 12%, vitamin C 1.6% 9%, vitamin B 1.2% 6.3% by weight percentage.The application method of the formula is by described formula and deionized water in mass ratio 0.8 1.2：9 mixing, are heated to 40 DEG C of constant temperature stirring 10min, room temperature are then naturally cooled under agitation.Formula provided by the present invention can reduce protona in scalp and hair follicle as 5a reductase inhibitors external preparation, improve and strengthen 5a reduction enzyme inhibitions；Used by the collocation with vitamin B, so as to strengthen the absorption and effect of vitamin B, improve the effect that nonanedioyl Diglycocol potassium suppresses 5a reductases；The CBF of scalp capillary can be improved by being coordinated by hesperidin methyl and vitamin C, be conducive to the growth of hair, played the effect as minoxidil.
Description
Technical field
It is a kind of formula for treating androgenetic alopecia, containing the formula specifically the invention belongs to field of medicaments
The application method of shampoo and the formula.
Background technology
It is bald that male pattern alopecia (MPA) is also known as androgenetic alopecia, hereditary alopecia, alopecia seborrheica and morning.According to statistics, exist
About 95% belongs to male pattern alopecia in hair loss patient.This disease is mainly in the male of 20~30 years old, with advancing age, and it is fallen ill
Rate is also in increasing trend.Although there is " male " two word in disease name, the patent of this not male, women equally can also suffer from
Disease.Male pattern alopecia is a kind of disease by multifactor impact, medical science discovered in recent years, the disease mainly with 5a- reductases and
DHT (protona) level is related.
Hair comes out from root of hair (hair follicle) borough chief, hair matrix cell and melanocyte in hair follicle, constantly propagation, closes
And into keratin, then harden and lose biochemical activity, come outbreak out in hair follicle, that is, grow hair.The growth cycle of hair, can
It is divided into growth period, catagen and stand-down three phases.The growth period of a piece hair is 5-7, catagen 2-3 weeks, stand-down
About 3 months.The mankind probably have 100,000 hairs, and growth period hair accounts for 95%.Catagen and stand-down account for 5%.Stand-down
After epilation, the hair that new " growth period " is had again is grown, and the mankind will be a healthy hair all the time.However, when one
There are more very sensitive 5a- reductases in the cytoplasm of the hair matrix cell of people, by the testosterone manufactured in vivo, with blood
Liquid cycles to reach hair follicle, into hair matrix cell, under the catalytic action of 5a- reductases, and being converted into protona, (its hero swashs
The effect of element is stronger than in the past 5 times).Double hydrogen testis trunks enter the nucleus of crown hair follicle, make the manufacture of its energy matter be obstructed, enter
And making the biosynthesis block of hair protein, hair matrix cell will shift to an earlier date apoptosis, the hair as " stand-down ".That is, head
Send out " growth period " and shorten, enter in advance " stand-down ", and this phase hair only about life-span of 3 months, when new hair also
When not being in time for longer, old hair begins to come off, and therefore androgenetic alopecia just there occurs.Also there is androgen in women body,
Therefore, it can also suffer from " androgenetic alopecia ".
Male's male is de- to show as hair line retrogressing, overhead alopecia.It can be divided into I types by Hamilton typing parting：
Puberty normal hairdo；II types：Bilateral hair line is slightly retreated；Type III：Frontal temporal part is substantially shunk back, and " M " type is presented；IV types：Before
Moved after volume, crown tuorbillion position is sparse, but without completely falling off；V-type：Frontal temporal part and top alopecia, centre forms broken belt；VI
Type：Alopecia spot is merged, and forehead comes off substantially, and crown trend continues to expand, only every narrow hair band；VII types：Only deposit marginal zone one
The hair of circle.Women male is bald, generally than man occur it is late, development slowly, mild symptoms.Main Women report is carried out for hair
Property it is sparse, present dispersivity distribution, be a kind of alopecia generalisata slowly developed, the great number person of getting a bit thin on top is few.More due to habits and customs
Disorderly, endocrinopathy causes caused by androgen increase.
Alopeciaing therapeutic must accomplish the early quantity and density for finding hair follicle on early treatment, everyone scalp at birth
Just have determined that, each hair follicle all one's life can only grow 20-25 root hairs, afterwards just not regrowth hair.If treated not in time,
The concentration of scalp dioxygen testis trunk is reduced after the hair tonic potentiality of hair follicle exhaust, then by suppressing the activity of 5a- reductases, is also given birth to
Do not go out and newly send.
Protona is the product that testosterone reduces enzymatic in target tissue through 5a-, is distributed widely in systemic blood.It is double
Hydrogen testosterone can combine to form compound with specific receptor and enter cell, then connects and combined with chromatin, Jin Erying with nuclear receptor
Ring RNA and DNA synthesis and play a series of physiological actions.After male's adult, if protona excess, it will produce such as
The pathological phenomenons such as whelk, alopecia.Recent studies proves that II type 5a- reductases are largely present in hair follicle root sheath, prostate, end
Last blood vessel, epididymis, fetus genital skin and be grown up genital skin fibroblast in.Testosterone reduces enzymatic conversion through 5a-
The protona (DHT) of formation makes hair follicle atrophy, cause trichomadesis, and this sex hormone is reduced to non reversibility.It is this
The reduction process of sex hormone only occurs in the hair follicle of forehead and overhead, and the hair of cephalic region and back of head is protected by longevity gene
Shield, such a reaction does not occur, therefore hair is not fallen off.Pass through the serum DHT water to male pattern alopecia group and Normal group crowd
Flat detection and compare, it is found that male pattern alopecia patient organizes serum DHT levels apparently higher than Normal group, further demonstrate
Testosterone is combined with 5a- reductases is converted into protona, and protona causes alopecia.
If androgenetic alopecia is not added with treatment, sexual development will be carried out, but if initial stage, control was proper, will be changed
It is kind, and delay the alopecia time.It is the activity by suppressing 5a- reductases to suppress 5a- reductases, to reduce internal dioxygen testis trunk
Concentration can help to solve the problems, such as alopecia.The method for the treatment of androgenetic alopecia has two kinds at present：Medicine and hair transplant.Medicine side
Face, is the hair loss state of atrophy primarily directed to alopecia initial stage or hair follicle.Maximally effective group of androgenetic alopecia is treated at present
Be combined into Finasteride+minoxidil, Finasteride (guarantor's method is stopped) and minoxidil are the medical anti-alopecias of U.S. FDA certification, it is non-that
Male amine (guarantor's method is stopped) is mainly used in orally, playing a role for the influence of hair follicle by reducing male sex hormone, and Finasteride (is protected
Method is stopped) internal 5a- reductases can be suppressed, so may refrain from the generation of protona, the present invention reduces enzyme level as 5a-
Agent external preparation can reduce protona in scalp and hair follicle, improve and strengthen 5a- reduction enzyme inhibitions.Minoxidil is used for outer
Apply, be divided into two kinds of 2% concentration (unisex) and 5% (male), mainly extend hair follicles cycle, keep blood supply to lead to
Freely, hair follicle nutrient absorption is promoted to carry out hair tonic, it is adaptable to which various types of alopecias, minoxidil is a kind of peripheral vasodilation medicine,
It is local long-term in use, the hair growth of male pattern alopecia and patients with alopecia areata can be stimulated.The medicine of outer painting, selectable range compared with
Narrow, the external preparation of product and suppression 5a- reductase of the in the market almost without alternative minot place has filled up 5a- also
The blank of reductase inhibitor external preparation.
The content of the invention
The present invention seeks to aimed to provide it is a kind of safely, have no side effect, to treat androgenetic alopecia effect good, alternative
Minoxidil and the simultaneously formula of the external preparation of suppression 5a- reductases, and the shampoo containing the formula, the formula
Application method.
To realize above-mentioned technical purpose, the technical solution adopted by the present invention is as follows：
A kind of formula for being used to treat androgenetic alopecia, by weight percentage including nonanedioyl Diglycocol potassium 41%-
50%th, Water-soluble Hesperidin 6%-12%, vitamin C 1.6%-9%, vitamin B 1.2%-6.3%.
Azelaic acid, popular name azalaic acid, it has the characteristics that：1. antibacterial action, suppresses the protein synthesis of bacterium, directly
Connect suppression and kill skin surface and intrafollicular bacterium, during higher concentration (>250mmol/L), to MRSE, verdigris
False unicellular bacterium, proteus, Candida albicans, propionibacterium acnes etc. have killing action, and minimum inhibitory concentration is 25mmol/
L, it is played a role dependent on PH, and intracellular performance antibacterial action can be comparatively fast entered when PH is low, and azelaic acid penetrates into exception
The dose of cell is more than normal cell；2. suppressing the generation of free radical, the generation of inhibitory activity oxygen radical plays anti-inflammatory and made
In vitro can inhibitory activity the oxygen groups hydroxylation and arachidonic peroxide of the aromatic compound that induce with, azelaic acid
Change is acted on；3. preventing Keratoderma, there is anti-keratinization to act on the skin of normal skin and acne infection, reduce thread keratin
Synthesis, prevent follicular hyperkeratosis；4. the influence of pair pigment cell of skin：One side azelaic acid is thin to melanocyte hyperactivity
The competitive inhibitory action of tyrosinase of intracellular, reduces pigment synthesis, but does not suppress the synthesis of the pigment of normal pegmentation cell,
On the other hand, it can destroy melanocyte mitochondrial respiratory chain, suppress the synthesis of cell DNA, hinder the increasing of abnormal melanocyte
Grow.Because it has above feature, it is usually used to make beauty skin care product, treats face acnes.
Azelaic acid also has regulation sebaceous glands function, and contestable suppresses the effect of 5a- reductases, and the hero for suppressing excessive swashs
Element is converted into protona, and the skin oil and fat for reducing the induction of protona factor is excessive.Azelaic acid turns out to be one by many-side
The strong 5a- reductases anticatalyst in human body skin is planted, in British Journal of Dermatology
(Stamatiadis.1988；119:A 627-632) research of report, under 3mmol/l, 5a- reductases are almost complete
(98%) it is suppressed.So being used as DHT inhibitors with it so as to anti-alopecia-stopping.Because its is insoluble, fusing point height and consumption
Greatly, easy to change, compatibility is poor, it is very limited in application, the present invention uses the derivative nonyl two of azelaic acid herein
Acyl Diglycocol potassium, its is soluble in water, and it has excellent safety and stability compared with azelaic acid, through fourth phase clinical safety
Have no side effect.
In addition, through clinical discovery by azelaic acid or derivatives thereof and vitamin B complex with the use of can play mutually enhancing with
The effect of promotion.
Aurantiamarin (also known as dried orange peel glycosides or hesperidin) is primarily present in the pericarp, fruit juice and seed of Rutaceae citrus
In, at most, content is about 3% to content especially in pericarp.Aurantiamarin belongs to Flavanones compound, nontoxic, and human body can not be closed
Into.Clinically frequently as the adjuvant and hemostatic for the treatment of hypertension.Aurantiamarin has the same efficiency of citrin, is given birth to dimension
Plain C collocation is used, and can strengthen ascorbic effect, and has stronger antiviral and antibacterial action, and heavy dose can suppress influenza disease
The breeding of poison；It can suppress to cause the effect of the tyrosinase of skin darkening, available for skin diseases such as treatment blackspot, freckles.Have
The normal permeability of blood vessel is maintained, capillary hemorrhage, bleeding gums etc. are prevented and treat.Capillary resistance can be strengthened, increased
The elasticity and toughness of strong capillary, make capillary infiltration normal, the blood of scalp capillary can be improved with vitamin C cooperation
Flow, is conducive to the growth (Kawaguchi, Goro. Japanese Laid-Open Patent Publication 93,17,321) of hair.With minoxidil
The mechanism of action is consistent.Current aurantiamarin has certain application in medicine, cosmetic industry, but effect is not notable, this mainly with
It is insoluble in water, and the characteristic insoluble in fat-soluble solvent is relevant.Therefore, should be from the Water-soluble Hesperidin after being modified.
There is the nonanedioyl Diglycocol potassium that the present invention is used contestable to suppress the effect of 5a- reductases, suppress excessive
Androgen conversion be protona, it is excessive to reduce the skin oil and fat that protona factor induces, and can be solved from root male sharp
Disposition alopecia, improves as 5a- reductase inhibitors external preparation and strengthens 5a- reduction enzyme inhibitions；From clinically finding,
Vitamin B of arranging in pairs or groups simultaneously is used, and can be mutually promoted and humidification；Water-soluble Hesperidin can strengthen capillary resistance,
Strengthen the elasticity and toughness of capillary, make capillary infiltration normal, scalp capillary can be improved with vitamin C cooperation
CBF, is conducive to the growth of hair, consistent with the minoxidil mechanism of action, can reach the effect as minoxidil.
Further limit, also including cacumen biotae alcohol extracting thing 10.5%-28%, propolis 3.4%-12%.
Cacumen biotae (also known as Japan cypress, gold zone cypress) is aiphyllium, and its spray, leaf and fruit can all be used as medicine, its bitter, puckery, property
It is slightly cold, enters lung, liver, large intestine channel, there is that cooling blood and hemostasis, black beard and hair, cough-relieving are breathed heavily.It is mainly used in bleeding caused by blood-heat bleeding
Illness, and have the effect such as antibechic, eliminating the phlegm, step-down, Anti-hair loss.Cacumen biotae alcohol extracting thing is to leucocyte LTB4 and 5-HETE (5- fat
Oxygenase) biosynthesis have stronger inhibitory action, also show the inhibitory action stronger to cyclo-oxygenase, cacumen biotae is logical
Cross and suppress the activity of 5- LOXs and the composition of Cycloxygenase to play antiinflammatory action.There is inhibitory action to S. aureus L-forms, and it is right
Micrococcus catarrhalis also has inhibitory action.The extract of cacumen biotae contains phenolic substance, it may have the effect of Anti-candida activity, androgen
Property alopecia pathogenesis be not fully understood, microorganism driving inflammatory response abut hair follicle, may be with hair state
It is abnormal relevant.And the anti-microbial property of cacumen biotae helps to nurse one's health scalp, improve scalp environment.
Propolis is the active principle that honeybee is used to maintain whole Population Health, the antibacterial having, beautifying face and moistering lotion, promotion cell
Effect of regeneration, is a kind of natural resources of extremely rareness, is assigned the title of " purple gold ".Recently, Japanese Scientists are ground
Study carefully and new foundation is provided to effect of hair for propolis, during this investigation it turned out, can they have studied propolis stimulate the head of mouse
Grow.As a result show, propolis promotes the growth of hair by inducing keratosis pilaris cell propagation, therefore for promoting after hair tonic
The benign growths of " floss " of generation.
Further limit, also including azone 6%-12%, EDTA-2Na 0.01%-0.03%.
Further limit, azone (AZONE) is highly effective skin penetration enhancer, has very strong to hydrophilic and lipophilic drugs
Transdermal effect, can increase the absorption of medicine, so as to strengthen curative effect of medication；EDTA-2Na is used for the pH value for adjusting formula.
Further limit, the Water-soluble Hesperidin is hesperidin methyl.
The solubility of hesperidin methyl is 12500 times of conventional aurantiamarin, and solubility is more than 25% in water.
Further limit, the vitamin B is vitamin B5 0.7%-3.5%, vitamin B6 0.5%-2%, vitamin
B80.5%-2%.
Vitamin B5 is infiltrative NMF, there is good penetration, can be easily penetrated into root of hair, there is hair soft
Elastic easily to comb, skin works after absorbing with B6 mono- can increase the sodium hyaluronate content of skin, and can stimulate cell division again
Raw and repair tissue；Vitamin B6 can improve fat secretion, regulation skin oil and fat balance；Vitamin B8 (also known as biotin), be
Promote the base substance of keratin growth, be also the basis that human body binds material, hair can cause hair loss, osteoporosis during shortage
Shape, research report points out that biotin can treat the alopecia caused by egg-white injury, and improvement hair is easily broken, hair quality is bad
Shortcoming.
Present invention also offers the application method using this formula, by above-mentioned formula and deionized water 0.8- in mass ratio
1.2：9 mixing, are heated to 40 DEG C of constant temperature stirring 10min, room temperature are then naturally cooled under agitation.
Present invention also offers the shampoo containing this formula, include that 95g-120g is above-mentioned to be matched somebody with somebody per 1000ml shampoos
Side.
Further limit, at 30 DEG C, the pH value of shampoo is 5.5-6.2, and viscosity is 6000-8000MPa.s.
Formula provided by the present invention suppresses the effect of 5a- reductases using nonanedioyl Diglycocol potassium, suppresses excessively
Androgen conversion is protona, and the skin oil and fat for reducing the induction of protona factor is excessive, and androgen can be solved from root
Property alopecia, as 5a- reductase inhibitors external preparation improve strengthen 5a- reduction enzyme inhibition；By with vitamin B
Collocation is used, so as to strengthen the effect of nonanedioyl Diglycocol potassium and vitamin B, is improved nonanedioyl Diglycocol potassium and is suppressed 5a-
The effect of reductase；Capillary resistance can be strengthened by hesperidin methyl, strengthen the elasticity and toughness of capillary, make hair
Thin Vascular permeability is normal, and the CBF of scalp capillary can be improved by coordinating with vitamin C, be conducive to the growth of hair, played
Effect as minoxidil；Help to nurse one's health scalp using the anti-microbial property of cacumen biotae alcohol extracting thing simultaneously, improve scalp ring
Border；Promote the benign growths of " floss " generated after hair tonic using propolis.
The present invention, which provides the formula, the preparation of outer painting is made by dissolving in deionized water, be easy to smear, and apply
It will not feel after smearing greasy uncomfortable.
Formula provided by the present invention, which can also be added in common shampoo base fluid, is made shampoo.
Embodiment
In order that the present invention may be better understood in those skilled in the art, with reference to embodiment to the technology of the present invention
Scheme is further illustrated.
A kind of formula for being used to treat androgenetic alopecia, by weight percentage including nonanedioyl Diglycocol potassium 41%-
50%th, Water-soluble Hesperidin 6%-12%, vitamin C 1.6%-9%, vitamin B 1.2%-6.3%.
Also include cacumen biotae alcohol extracting thing 10.5%-28%, propolis 3.4%-12%, azone 6%-12%, EDTA-2Na
0.01%-0.03%.
Wherein described Water-soluble Hesperidin is hesperidin methyl.
The vitamin B is vitamin B5 0.7%-3.5%, vitamin B6 0.5%-2%, vitamin B8 0.5%-2%.
Embodiment one
Prepare the outer painting preparation for also having the formula：
Nonanedioyl Diglycocol potassium 50.00g, Cacumen Platycladi extract 20.00g, azone 10.00g, hesperidin methyl are taken respectively
10.00g, vitamin C 6.00g, vitamin B5 2.00g, vitamin B6 1.00g, vitamin B8 1.00g, propolis 8.00g,
EDTA-2Na0.02g, deionized water adds to 1000ml, is heated to 40 DEG C of constant temperature stirring 10min, then natural cooling under agitation
Outer painting preparation is obtained to room temperature.
Embodiment two
Prepare the shampoo containing the formula：
Step one, A1 is introduced into production pot, under scraping stirring after high speed shear homogeneous about 5min, under homogeneous stirring
A2 is added, then 85 DEG C or so constant temperature scraping stir about 30min are heated under scraping stirring, then will under homogeneous stirring
A3 is added, and is then circulated cooling under scraping stirring, when being cooled to less than 40 DEG C, is transferred in deposit pot, will be damaged in right amount
Water consumption is added, after then naturally cooling to room temperature under scraping stirring, is used as deposit base-material；
Step 2, B1 is introduced into production pot, and under scraping stirring after high speed shear homogeneous about 2min, B2 is added,
After the lower high speed shear homogeneous of scraping stirring about 3min, B3 is added, being then heated to 85 DEG C or so constant temperature under scraping stirring scrapes
Side stir about 30min, then adds B4 under homogeneous stirring, is then circulated cooling under scraping stirring, is cooled to 40
DEG C or so when, under homogeneous stirring water and B5 will be lost in right amount adds, and then scraping stir about 5min, then adds B6, and
The volume for adding deionized water regulation shampoo according to actual conditions adds sodium chloride, citric acid regulation shampoo to 1000ml
Shampoo pH value be 5.5-6.2, viscosity is 6000-8000MPa.s, while scraping stir progress high speed shear homogeneous
After about 2min, continue scraping stir about 5min.
Wherein A1, A2, A3, B1, B2, B3, B4, B5, B6 material included and content such as following table：
Choose the clinical research of 12 months by a definite date that 800 subjects of 18 years old to 41 years old participate in, wherein women accounting
10%, male's accounting 90%；Male subject presses Hamilton typing parting, wherein II types subject accounting 20%, type III
Subject's accounting 25%, IV type subjects accounting 25%, V-type subject accounting 20%.Subject is equally divided into four groups, it is each
Group contains female subjects, II types subject, type III subject, IV types subject, V-type subject.First group of subject makes
With the preparation prepared in embodiment one, each 2ml, 2 times a day, is applied to scalp；Second group of subject is used in embodiment two
The shampoo of preparation, is washed once for every two days using the shampoo；3rd group of subject uses the preparation for removing vitamin B, other
Composition is consistent with embodiment one；4th group of subject uses the shampoo for removing nonanedioyl Diglycocol potassium, other compositions
It is consistent with embodiment one.
The growth of hair is assessed in research using four indices, i.e.,：Hair is counted, expert group of dept. of dermatology does according to photo
Grade assessment, the assessment of researcher and the self-assessment of patient.
Following data are obtained with chasing after this 800 subjects：
According to upper table as can be seen that after using the preparation provided in embodiment one, thering is 70% subject to stop alopecia, approaching
The people for having 69% has grown new hair at alopecia position；After the shampoo provided in embodiment two, also have close to 65%
Subject stops alopecia, and 55% or so subject has grown new hair；And in the 3rd group and the 4th group of control group, the 3rd
Group is because eliminating vitamin B, and the 4th group because lacking nonanedioyl Diglycocol potassium so that effect is had a greatly reduced quality, here from the one hand
It can reflect, vitamin B is used with the collocation of nonanedioyl Diglycocol potassium make it that the effect of hair growth is more preferable.
The present invention is provided above is a kind of for treating making for the formula, shampoo and the formula of androgenetic alopecia
It is described in detail with method.The explanation of specific embodiment is only intended to help and understands that the method for the present invention and its core are thought
Think.It should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention, may be used also
To carry out some improvement and modification to the present invention, these are improved and modification is also fallen into the protection domain of the claims in the present invention.
Claims (8)
1. a kind of formula for being used to treat androgenetic alopecia, it is characterised in that：Include the sweet ammonia of nonanedioyl two by weight percentage
Sour potassium 41%-50%, Water-soluble Hesperidin 6%-12%, vitamin C 1.6%-9%, vitamin B 1.2%-6.3%.
2. a kind of formula for being used to treat androgenetic alopecia according to claim 1, it is characterised in that：Also include arbor-vitae
Leaf-alcohol extract 10.5%-28%, propolis 3.4%-12%.
3. a kind of formula for being used to treat androgenetic alopecia according to claim 1 or 2, it is characterised in that：Also include
Azone 6%-12%, EDTA-2Na 0.01%-0.03%.
4. a kind of formula for being used to treat androgenetic alopecia according to claim 1 or 2, it is characterised in that：The water
Dissolubility aurantiamarin is hesperidin methyl.
5. a kind of formula for being used to treat androgenetic alopecia according to claim 4, it is characterised in that：The vitamin
B is vitamin B5 0.7%-3.5%, vitamin B6 0.5%-2%, vitamin B8 0.5%-2%.
6. a kind of application method for being used to treat the formula of androgenetic alopecia, it is characterised in that：The claims 1-5 is appointed
Formula and deionized water 0.8-1.2 in mass ratio described in one：9 mixing, are heated to 40 DEG C of constant temperature stirrings 10min, Ran Hou
Room temperature is naturally cooled under stirring.
7. a kind of shampoo containing for treating androgenetic alopecia formula, it is characterised in that：Include per 1000ml shampoos
Formula described in 95g-120g the claims any one of 1-5.
8. a kind of shampoo containing for treating androgenetic alopecia formula according to claim 7, it is characterised in that：
At 30 DEG C, the pH value of shampoo is 5.5-6.2, and viscosity is 6000-8000MPa.s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710263979.5A CN106937957B (en) | 2017-04-21 | 2017-04-21 | Composition for treating androgenetic alopecia and shampoo thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710263979.5A CN106937957B (en) | 2017-04-21 | 2017-04-21 | Composition for treating androgenetic alopecia and shampoo thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106937957A true CN106937957A (en) | 2017-07-11 |
| CN106937957B CN106937957B (en) | 2021-03-30 |
Family
ID=59463792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710263979.5A Active CN106937957B (en) | 2017-04-21 | 2017-04-21 | Composition for treating androgenetic alopecia and shampoo thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106937957B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109355401A (en) * | 2018-12-14 | 2019-02-19 | 江颖纯 | A kind of relevant gene loci library of hair and its application |
| CN110882173A (en) * | 2019-12-05 | 2020-03-17 | 西北农林科技大学 | Formula of external daily chemical for preventing and treating alopecia by targeting hair follicle stem cells |
| EP3815683A1 (en) * | 2019-10-31 | 2021-05-05 | Valetudo S.r.l. Con Unico Socio | Formulation or remedy against androgenetic alopecia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893909A (en) * | 2003-12-18 | 2007-01-10 | 雀巢技术公司 | Composition for improving skin, hair and coat health containing flavanones |
| CN101596318A (en) * | 2008-06-04 | 2009-12-09 | 北京普润生物科技发展有限公司 | The external preparation of treatment androgens psilosis and seborrheic dermatitis, acne |
-
2017
- 2017-04-21 CN CN201710263979.5A patent/CN106937957B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1893909A (en) * | 2003-12-18 | 2007-01-10 | 雀巢技术公司 | Composition for improving skin, hair and coat health containing flavanones |
| CN101596318A (en) * | 2008-06-04 | 2009-12-09 | 北京普润生物科技发展有限公司 | The external preparation of treatment androgens psilosis and seborrheic dermatitis, acne |
Non-Patent Citations (5)
| Title |
|---|
| 何昕: "《蜜蜂养殖与利用》", 30 April 2013, 中原农民出版社 * |
| 张传义等: "《现代中药药理与临床》", 30 June 2004, 南海出版公司 * |
| 罗健: "《人生健康计划：您的健康我做主》", 31 October 2013, 人民军医出版社 * |
| 裘炳毅等: "《现代化妆品科学与技术：全3册》", 31 March 2016, 中国轻工业出版社 * |
| 马莉: "《维生素保健康全书》", 30 May 2013, 天津科学技术出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109355401A (en) * | 2018-12-14 | 2019-02-19 | 江颖纯 | A kind of relevant gene loci library of hair and its application |
| EP3815683A1 (en) * | 2019-10-31 | 2021-05-05 | Valetudo S.r.l. Con Unico Socio | Formulation or remedy against androgenetic alopecia |
| CN110882173A (en) * | 2019-12-05 | 2020-03-17 | 西北农林科技大学 | Formula of external daily chemical for preventing and treating alopecia by targeting hair follicle stem cells |
| CN110882173B (en) * | 2019-12-05 | 2022-06-17 | 西北农林科技大学 | Formula of external daily chemical for preventing and treating alopecia by targeting hair follicle stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106937957B (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4603192B2 (en) | Hair scalp composition | |
| TWI480057B (en) | Use of caffeamide derivative | |
| KR20120039384A (en) | The hair growth compositions containing flavonoids | |
| CN106937957A (en) | A kind of application method for being used to treat the formula, shampoo and the formula of androgenetic alopecia | |
| JP2023517413A (en) | Hair care composition and method for its preparation | |
| JP3321712B2 (en) | Topical hair restorer containing pine extract | |
| US20190269738A1 (en) | Camelid compound(s), composition(s) and method(s) | |
| AU2014361754A1 (en) | Method of treatment of alopecia with monoterpenoids | |
| CN110064039B (en) | Anti-hair loss and hair-nourishing composition and application thereof | |
| JP3451184B2 (en) | Cosmetic composition or pharmaceutical composition | |
| CN112220794A (en) | Application of citric acid in preventing alopecia and promoting hair growth | |
| RU2381786C2 (en) | Method of treating hair growth disorder, such as female pattern of hair loss, and compositions applied therein | |
| US20080241285A1 (en) | Compositions and Methods to Treat Alopecia | |
| KR20120051199A (en) | Cosmetic compositions for hair or scalp to prevent hair loss and promote growing hair | |
| JPH03112912A (en) | Cosmetic composition | |
| Pingale et al. | A review on alopecia and its remedies | |
| CN113633585B (en) | External hair care composition and preparation with effects of preventing alopecia, promoting hair growth and blackening hair and preparation method thereof | |
| JP5414137B2 (en) | Hyaluronidase activity inhibitor | |
| JP5902184B2 (en) | Hair growth promoter, eyelash and eyebrow growth promoter, and hair loss inhibitor | |
| KR20020008268A (en) | Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois | |
| CN104257564A (en) | Hair growing and blackening shampoo and preparation method thereof | |
| KR100308491B1 (en) | Composition for growthing hair | |
| US20240189201A1 (en) | Hair serum and supplement | |
| JP7222483B2 (en) | Method for preparing cycad extract | |
| CN117323278A (en) | Hair loss prevention nursing agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |